In 2 recent studies published in NEJM, both essentially show that DES and bare metal stents have similar safety profiles, but that DES have lower restenosis rates. The first study looked at outcomes of almost 30,000 patients in a large Swedish registry that had a single stent, and found no difference in death or MI, but much lower clinical restenosis in the DES patients (abstract). The other RCT of over 3000 STEMI patients found no difference in death or thrombosis between the stent types, but the DES group required fewer revasularizations (abstract). Both of these trials support the use of DES in those able and willing to continue long-term dual anti-platelet therapy.
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]